content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Fibrocell Science, Inc. (FCSC)

2.16
-0.05
(-2.26%)
Sep 11, 4:00PM EDT
content_middle

Fibrocell Science (FCSC), an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints.

FCSC’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

FCSC has a collaboration agreement with Intrexon Corporation (XON)for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.

The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009; was incorporated in 1992 and is based in Exton, Pennsylvania.

Previous Close: 
3.30
Open: 
3.22
Bid: 
2.12
Ask: 
3.47
1yr Target Price: 
5.40
Day's Range: 
3.02 - 3.35
52wk Range: 
1.75 - 18.92
Volume: 
91746
Average Daily Volume: 
86378
Market Capitalization: 
20.12M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
9.31M
content_right

Pages